Suh Winston, Master Samip, Liu Lihong, Mills Glenn, Shi Runhua
Hematology-Oncology, Feist-Weiller Cancer Center, Louisiana State University Health Shreveport, Shreveport, USA.
Cureus. 2021 Feb 13;13(2):e13329. doi: 10.7759/cureus.13329.
Background Disparities in access to care and proper treatment can have significant implications in patient survival outcome and mortality. This retrospective study of prostate cancer patients from the National Cancer Database (NCDB) between the years 2004 and 2014 and follow-up to the end of 2015 analyzed such effects that variation in payer status might have on outcome. Methods This study used the data of 696,321 diagnosed prostate cancer patients from the NCDB for the years 2004 to 2014 and follow-up to the end of 2015 to analyze the effect that payer status would have on prostate cancer survival. Multivariable cox regression was used to study the hazard ratios (HRs) of payer status and other variables along with the Charlson Comorbidity Index to analyze their associated increased risk of death. Statistical software SAS 9.4 for Windows was used to analyze the overall survival (OS) of patients on different insurance plans along with variations in prostate-specific antigen (PSA) levels and treatment type. Results When looking at OS, those with private insurance had the greatest overall survivability while those on Medicare were the only ones who reached the median OS. In contrast to those who had private insurance, those who had Medicare, the uninsured, and those with Medicaid demonstrated significantly greater risks of death at 43%, 58%, and 69% increased risk of death, respectively. In addition to payer status, other variables were also significant predictors of OS, including demographic factors (age, race), comorbidities, socioeconomic status (income, education), distance traveled to facility, type of facility, treatment delay, treatment modality, PSA levels at diagnosis, and cancer stage at diagnosis. Conclusion Payer status is intricately linked to a number of other variables that might affect survival. Even after adjustment for a number of these factors, insurance status was shown to have a significant effect on prostate cancer survivorship. In contrast to those who had private insurance, those who had Medicare, the uninsured, and those with Medicaid demonstrated significantly greater risks of death at 43%, 58%, and 69% increased risk of death, respectively. Studies have suggested that those without insurance or on Medicaid are less likely to undergo screening and have worse health-related quality of life, while those on Medicare may be deterred from continuing treatment due to high out-of-pocket costs. However, the complete mechanism behind the improved survivorship of those on private insurance is unclear. The effect of payer status on quality of life may be an interest that needs to be further studied. Further research will be required to provide definite reasons for these observations and mediation analysis of other factors could prove to be valuable.
获得医疗服务和适当治疗方面的差异可能对患者的生存结果和死亡率产生重大影响。这项对2004年至2014年期间来自国家癌症数据库(NCDB)的前列腺癌患者进行的回顾性研究,并随访至2015年底,分析了支付者状态的变化可能对结果产生的此类影响。
本研究使用了NCDB中2004年至2014年期间696321例确诊前列腺癌患者的数据,并随访至2015年底,以分析支付者状态对前列腺癌生存的影响。多变量cox回归用于研究支付者状态和其他变量以及查尔森合并症指数的风险比(HRs),以分析它们相关的死亡风险增加情况。使用Windows版统计软件SAS 9.4分析不同保险计划患者的总生存期(OS)以及前列腺特异性抗原(PSA)水平和治疗类型的变化。
在观察总生存期时,拥有私人保险的患者总体生存率最高,而只有参加医疗保险的患者达到了总生存期的中位数。与拥有私人保险的患者相比,参加医疗保险的患者、未参保患者和参加医疗补助的患者的死亡风险分别显著增加43%、58%和69%。除了支付者状态外,其他变量也是总生存期的重要预测因素,包括人口统计学因素(年龄、种族)、合并症、社会经济地位(收入、教育程度)、前往医疗机构的距离、医疗机构类型、治疗延迟、治疗方式、诊断时的PSA水平和诊断时的癌症分期。
支付者状态与许多可能影响生存的其他变量密切相关。即使对其中一些因素进行调整后,保险状态仍显示对前列腺癌的生存有显著影响。与拥有私人保险的患者相比,参加医疗保险的患者、未参保患者和参加医疗补助的患者的死亡风险分别显著增加43%、58%和69%。研究表明,没有保险或参加医疗补助的人接受筛查的可能性较小,健康相关生活质量较差,而参加医疗保险的人可能因自付费用高而不愿继续治疗。然而,私人保险患者生存率提高背后的完整机制尚不清楚。支付者状态对生活质量的影响可能是一个需要进一步研究的问题。需要进一步的研究来为这些观察结果提供明确的原因,对其他因素的中介分析可能会被证明是有价值的。